# Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma

> **NCT00911560** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 374 (actual)

## Conditions studied

- Neuroblastoma

## Interventions

- **BIOLOGICAL:** adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH
- **BIOLOGICAL:** oral β-glucan

## Key facts

- **NCT ID:** NCT00911560
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2009-05-27
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 374 (ACTUAL)
- **Last updated:** 2025-06-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00911560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00911560, "Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00911560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*